Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Given Average Recommendation of “Moderate Buy” by Brokerages

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) has received a consensus recommendation of “Moderate Buy” from the eleven analysts that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $20.4545.

A number of equities analysts have issued reports on the company. Morgan Stanley reduced their target price on Compass Pathways from $18.00 to $16.00 and set an “overweight” rating on the stock in a report on Wednesday, March 25th. Canaccord Genuity Group reduced their target price on Compass Pathways from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, March 26th. Lifesci Capital upgraded Compass Pathways to a “strong-buy” rating in a report on Thursday, February 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Pathways in a report on Monday, April 20th. Finally, Compass Point set a $15.00 target price on Compass Pathways in a report on Thursday, February 12th.

Compass Pathways Price Performance

Compass Pathways stock opened at $9.01 on Monday. The company has a quick ratio of 0.77, a current ratio of 0.77 and a debt-to-equity ratio of 0.55. Compass Pathways has a 12-month low of $2.25 and a 12-month high of $10.21. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -2.92 and a beta of 2.39. The business’s 50-day simple moving average is $6.77 and its 200 day simple moving average is $6.53.

Compass Pathways (NASDAQ:CMPS) last issued its earnings results on Tuesday, March 24th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.59). As a group, research analysts anticipate that Compass Pathways will post -1.83 earnings per share for the current year.

Institutional Investors Weigh In On Compass Pathways

A number of hedge funds have recently modified their holdings of the business. Corient Private Wealth LLC raised its position in shares of Compass Pathways by 3.2% during the fourth quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock worth $265,000 after purchasing an additional 1,200 shares during the period. CWM LLC raised its position in shares of Compass Pathways by 19.2% during the third quarter. CWM LLC now owns 15,650 shares of the company’s stock worth $90,000 after purchasing an additional 2,525 shares during the period. Conservest Capital Advisors Inc. raised its position in shares of Compass Pathways by 24.6% during the fourth quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company’s stock worth $175,000 after purchasing an additional 5,000 shares during the period. Persistent Asset Partners Ltd acquired a new stake in shares of Compass Pathways during the fourth quarter worth about $38,000. Finally, Raymond James Financial Inc. raised its position in shares of Compass Pathways by 82.7% during the third quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock worth $79,000 after purchasing an additional 6,228 shares during the period. Institutional investors and hedge funds own 46.19% of the company’s stock.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.